ClinicalTrials.gg
Not yet recruitingNCT07744204LEAPUpdated Aug 19, 2026

LEAP Strategy for Neovascular Age-Related Macular Degeneration

An interventional study of Laser photocoagulation and Anti-VEGF agents in Neovascular Age-related Macular Degeneration(nAMD) and Wet Macular Degeneration, sponsored by Chinese PLA General Hospital. Not yet recruiting. Open to participants aged 50 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-08-19.

Sponsored by Chinese PLA General Hospital · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
50 Years to 99 Years
Sex
All
01

Study summary

Background: Age-related macular degeneration (AMD) is a common eye disease that can cause blindness in older adults. The "wet" form of AMD, called neovascular AMD, happens when abnormal blood vessels grow under the retina and leak fluid. The current standard treatment requires repeated eye injections of anti-VEGF drugs, often every month or every few months. This frequent injection schedule is a heavy burden for patients and many cannot keep up with the treatment plan.

Purpose: This study tests whether a single session of low-intensity laser applied to the diseased area, given just before the anti-VEGF injection, can help the drug reach the target more effectively. If this works, patients may need far fewer injections over time.

Intervention: Participants will be randomly assigned to one of two groups. The experimental group will receive the laser treatment followed by an anti-VEGF injection within 6 hours. The control group will receive the anti-VEGF injection alone, according to the current standard regimen. Four different anti-VEGF drugs are allowed in this study: conbercept, aflibercept, ranibizumab, and faricimab.

Participants: The study plans to enroll at least 240 patients with active neovascular AMD across five hospitals in China. All participants must be at least 50 years old and meet specific eligibility criteria.

Follow-up: All participants will be followed for 24 months with monthly clinic visits. The study will record the total number of injections received, changes in vision, fluid status on eye scans, and any side effects.

Primary Outcome: The main measure is the total number of anti-VEGF injections each participant needs over the 24-month period. The study will compare the experimental group and the control group to see whether the laser-enhanced approach reduces the injection frequency.

02

Conditions studied

  • Neovascular Age-related Macular Degeneration(nAMD)
  • Wet Macular Degeneration
03

In context

Wet Macular Degeneration

93 studies on the registry are indexed under Wet Macular Degeneration; 10 are open to participants now.

This study's planned enrollment of 240 is above the median of 101 across 74 interventional studies indexed under Wet Macular Degeneration.

Browse Wet Macular Degeneration studies →

Lead sponsor

Chinese PLA General Hospital is the lead sponsor of 574 studies on the registry; 209 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 50 years, male or female
  • Diagnosed with neovascular age-related macular degeneration (nAMD) based on multimodal imaging (fundus photography, OCT, FFA, ICGA), including type 1, type 2, or type 3 MNV, or PCV
  • Clear ocular media and adequate pupillary dilation to permit OCT, fundus photography, angiography, and laser photocoagulation
  • Active MNV in the study eye at least partially located ≥ 300 μm from the foveal centre
  • Willing and able to provide written
  • Only one eye per subject enrolled; if both eyes eligible, the study eye is selected by the investigator

Exclusion criteria

Exclusion Criteria:

  • Active MNV entirely located within 300 μm of the foveal centre
  • Significant hemorrhage obscuring the active MNV lesion on FFA/ICGA Unwilling or unable to provide , refusal of randomization, or inability to complete scheduled follow-up visits
  • Concurrent participation in other clinical trials
  • or allergy to FFA/ICGA
  • Coexisting ocular conditions that may affect visual acuity during follow-up (e.g., cataract, diabetic retinopathy, retinal vascular occlusion, uveitis, neovascular glaucoma)
  • Severe ocular surface infection (e.g., conjunctivitis, severe blepharitis)
  • Uncontrolled hypertension (blood pressure > 180/110 mmHg) despite antihypertensive therapy
  • Any condition in the study eye or systemically that, in the investigator's opinion, would pose significant risk to the participant
  • Poorly controlled blood glucose in diabetic patients
  • , stroke, myocardial infarction, acute congestive heart failure, or other acute cardiovascular event requiring hospitalization within the past 4 months
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    LEAP (Laser-Enhanced Anti-VEGF Precise Penetration)

    Participants in this arm receive a single session of 577-nm laser photocoagulation applied to the active macular neovascularization lesion (located ≥ 300 μm from the foveal centre), followed by an intravitreal injection of anti-VEGF agent (conbercept, aflibercept, ranibizumab, or faricimab) within 6 hours after laser. Retreatment during the 24-month follow-up is repeated when signs of active disease recur, using the same combination therapy.

    Device: Laser photocoagulation · Drug: Anti-VEGF agents

  • Active comparator
    Conventional Treatment Group

    Participants in this arm receive intravitreal injection of anti-VEGF agent (conbercept, aflibercept, ranibizumab, or faricimab) alone according to the standard 3+PRN (pro re nata) regimen. Retreatment during the 24-month follow-up is given when signs of active disease recur, using anti-VEGF injection alone.

    Drug: Anti-VEGF agents

Interventions

  • DeviceLaser photocoagulation

    577-nm yellow laser photocoagulation with a spot size of 200 μm, exposure time of 0.1-0.2 seconds, applied to the active macular neovascularization lesion located ≥ 300 μm from the foveal centre, with laser power adjusted to produce grade II to mild III burns. Laser is performed within one week after randomization and repeated when signs of active disease recur during follow-up.

  • DrugAnti-VEGF agents

    Intravitreal injection of anti-VEGF agents, including conbercept, aflibercept, ranibizumab, or faricimab. The specific drug is selected based on stratification and clinical indication. Injection is administered under sterile conditions using standard aseptic technique, with needle insertion 3.5-4 mm posterior to the limbus.

06

What researchers measure

Primary outcomes

  1. Total Number of Anti-VEGF Injections Over 24 Months

    The total number of intravitreal anti-VEGF injections administered to each participant during the 24-month follow-up period, compared between the LEAP group and the conventional treatment group.

    Time frame: 24 months

Secondary outcomes

  1. Change in Best-Corrected Visual Acuity

    Change in BCVA from baseline to 24 months, measured using the ETDRS logarithmic visual acuity chart at 4 meters.

    Time frame: Baseline to 24 months

  2. Incidence of Subretinal or Intraretinal Fluid

    Presence or absence of subretinal fluid and/or intraretinal fluid on optical coherence tomography (OCT) during follow-up.

    Time frame: 24 months

  3. Total Number of Injections by Drug Subgroup

    Comparison of the total number of anti-VEGF injections over 24 months among the four drug subgroups (conbercept, aflibercept, ranibizumab, faricimab), analyzed using a stratified Poisson regression model with interaction test between drug type and treatment regimen.

    Time frame: 24 months

  4. Change in NEI-VFQ-25 Composite Score

    Change from baseline to 24 months in the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) composite score. The NEI-VFQ-25 is a 25-item questionnaire assessing vision-related quality of life. Composite scores range from 0 to 100, with higher scores indicating better vision-related functioning.

    Time frame: Baseline to 24 months

  5. Change in EQ-5D-5L Utility Index

    Change from baseline to 24 months in the EuroQol Five-Dimension Five-Level (EQ-5D-5L) utility index. The EQ-5D-5L assesses health-related quality of life across five dimensions. The utility index ranges from -0.594 to 1.000 (using the Chinese value set), with higher scores indicating better health utility. If a secondary score (EQ-VAS) is also collected, it will be reported separately.

    Time frame: Baseline to 24 months

Other outcomes

  1. Safety and Adverse Events

    Incidence of adverse events, including corneal injury, ocular hypertension, lens injury, macular edema, retinal injury, and serious adverse events (endophthalmitis, retinal detachment, vitreous hemorrhage, choroidal detachment, etc.).

    Time frame: 24 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2026; primary completion for Jul 2029, 35 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2026
First posted
Aug 4, 2026
StartEst.
Aug 1, 2026
Primary completionEst.
Jul 31, 2029
CompletionEst.
Jul 31, 2029
Last update
Aug 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07744204
Collaborators
The 921st Hospital of the Joint Logistics Support Force of Chinese PLA, Shanghai Jiao Tong University Renji Hospital Sanya Hospital
Responsible party
Houbin Huang (Director, Senior Department of Ophthalmology, PLA General Hospital, Chinese PLA General Hospital) — Principal investigator
First posted
Aug 4, 2026
Start date
Aug 1, 2026 (estimated)
Primary completion
Jul 31, 2029 (estimated)
Completion
Jul 31, 2029 (estimated)
Last update
Aug 19, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion